Skip to main content

Market Overview

Tickers

Articles

Keywords

Search by keyword...
googlecse

Barclays Adjusts Price Targets On AK Steel, CONSOL Energy And Others

Davit Kirakosyan , Benzinga Staff Writer  
July 12, 2016 1:40pm   Comments
Share:
Barclays Adjusts Price Targets On AK Steel, CONSOL Energy And Others

Barclays raised its price targets for several metals and energy companies, including:

  • AK Steel Holding Corporation (NYSE: AKS) (Equal Weight): To $5 from $4
  • Alkermes Plc (NASDAQ: ALKS) (Overweight): To $65 from $50
  • CONSOL Energy Inc. (NYSE: CNX) (Equal Weight): To $14 from $12

    • Related Link: Mining The Metals Sector: Deutsche Bank Updates 3 Big Names

  • Nucor Corporation (NYSE: NUE) (Overweight): To $55 from $52
  • Steel Dynamics, Inc. (NASDAQ: STLD) (Overweight): To $28 from $27
  • United States Steel Corporation (NYSE: X) (Equal Weight): To $16 from $15

    • Did you like this article? Could it have been improved? Please email feedback@benzinga.com to let us know!

    Latest Ratings for AKS

    DateFirmActionFromTo
    Feb 2020CFRAUpgradesHoldBuy
    Dec 2019UBSUpgradesSellNeutral
    Dec 2019JP MorganUpgradesUnderweightNeutral

    View More Analyst Ratings for AKS
    View the Latest Analyst Ratings

    © 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

     

    Related Articles (ALKS + AKS)

    The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed
    The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts
    Earnings Scheduled For February 11, 2021
    The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement
    The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight
    The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study
    View Comments and Join the Discussion!

    Posted-In: BarclaysAnalyst Color Price Target Commodities Markets Analyst Ratings

    Don't Miss Any Updates!
    News Directly in Your Inbox
    Subscribe to:
    Benzinga Premarket Activity
    Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
    Market in 5 Minutes
    Everything you need to know about the market - quick & easy.
    Fintech Focus
    A daily collection of all things fintech, interesting developments and market updates.
    SPAC
    Everything you need to know about the latest SPAC news.
    Thank You

    Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com